US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DAMORA THERAPEUT

27.18

+0.91003.46%

Volume:97.46K

Turnover:2.63M

Market Cap:1.67B

PE:-2.75

High:27.71

Open:25.87

Low:25.63

Close:26.27

52wk High:38.33

52wk Low:2.53

Shares:61.55M

Float Shares:47.65M

Volume Ratio:0.70

T/O Rate:0.20%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-9.8764

EPS(LYR):-153.9532

ROE:-99.74%

ROA:-21.61%

PB:4.33

PE(LYR):-0.18

Loading ...

Overview Company News Filings

Damora Therapeutics Grants New Hires Options for 135,400 Shares at $28.18 Each

Damora Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Top News Today: Stocks Fall, Oil Rises as US-Iran Tensions Mount

Damora Therapeutics (DMRA) Starts CLARITY 101 Trial With Valuation Still In Focus

Simply Wall St.

Damora Therapeutics Director Andrew Cheng Files Initial Beneficial Ownership Statement

Jefferies Reaffirms Their Buy Rating on Damora Therapeutics (DMRA)

Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Damora Therapeutics (DMRA)

Damora Therapeutics Posts Corporate Deck on mutCALR-Targeted Therapies for Myeloproliferative Neoplasms

Press Release: Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Damora Q2 Net Loss Widens to $31.17 Million

Wedbush Keeps Their Buy Rating on Damora Therapeutics (DMRA)

Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis

MT Newswires Live

Damora Therapeutics Initiates Phase 1/1B Clarity-101 Clinical Trial of Dmr-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis

THOMSON REUTERS

Damora Therapeutics - Expects Initial Clarity-101 Trial Data Beginning Mid-2027

THOMSON REUTERS

Damora Therapeutics Grants 451,000 Inducement Stock Options at $28.99 Per Share

Damora Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

U.S. Research ROUNDUP-Blackstone, Hartford Insurance, Zevra Therapeutics

Damora Therapeutics Inc (pre-reincorporation) : Jefferies Initiates Coverage with Buy Rating; Price Target $50

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/DMRA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DMRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMRA\",,,,,undefined,":{"symbol":"DMRA","market":"US","secType":"STK","nameCN":"DAMORA THERAPEUT","latestPrice":27.18,"timestamp":1789054543651,"preClose":26.27,"halted":0,"volume":97461,"delay":0,"changeRate":0.0346402740768938,"floatShares":47648701,"shares":61553200,"eps":-9.876431,"marketStatus":"Trading","change":0.91,"latestTime":"09-10 11:35:53 EDT","open":25.87,"high":27.71,"low":25.63,"amount":2633352.3625499997,"amplitude":0.079178,"askPrice":27.23,"askSize":24,"bidPrice":27.09,"bidSize":772,"shortable":3,"etf":0,"ttmEps":-9.876431,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":2,"adr":0,"listingDate":1603944000000,"exchange":"NASDAQ","adjPreClose":26.27,"preHourTrading":{"tag":"盘前","latestPrice":26.8,"preClose":26.27,"latestTime":"07:13 EDT","volume":1,"amount":26.8,"timestamp":1789038795249,"change":0.53,"changeRate":0.020175,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":26,"preClose":26.27,"latestTime":"19:30 EDT","volume":5766,"amount":150932.35,"timestamp":1788996609268,"change":-0.27,"changeRate":-0.010278,"amplitude":0.010278},"volumeRatio":0.702536},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMRA\",,,,,undefined,":{"symbol":"DMRA","floatShares":47648701,"roa":"-21.61%","roe":"-99.74%","lyrEps":-153.953213,"volumeRatio":0.702536,"shares":61553200,"dividePrice":0,"high":27.71,"amplitude":0.079178,"preClose":26.27,"low":25.63,"week52Low":2.53,"pbRate":"4.33","week52High":38.3251,"institutionHeld":0,"latestPrice":27.18,"committee":0.939698,"eps":-9.876431,"divideRate":0,"volume":97461,"delay":0,"ttmEps":-9.876431,"open":25.87,"prevYearClose":23.01,"prevWeekClose":30.06,"prevMonthClose":28.18,"prevQuarterClose":26.01,"fiveDayClose":28.18,"twentyDayClose":31,"sixtyDayClose":20.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DMRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-12","symbol":"DMRA","fiscalQuarterEnding":"2026/03","expectedEps":-0.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.62},{"market":"US","date":"2026-03-19","symbol":"DMRA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773892800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-06","symbol":"DMRA","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-2.36},{"market":"US","date":"2025-08-05","symbol":"DMRA","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-2.6},{"market":"US","date":"2025-05-08","symbol":"DMRA","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-1.92}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DMRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DMRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":10,"updateTime":1785124800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DMRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DMRA","date":"2026-09-09","current":-2.659868,"percent":0.669355,"low":-100.260711,"twenty":-7.707644,"median":-7.192369,"eighty":-6.385103,"high":-5.207587,"avg":-12.437093,"sd":21.000133,"marketCap":1800825089},"quantilePoints":[{"date":"2026-03-13","current":-100.260711,"twenty":-100.260711,"median":-100.260711,"eighty":-98.29884,"marketCap":1588530698},{"date":"2026-03-20","current":-72.999835,"twenty":-100.199878,"median":-95.983376,"eighty":-84.763454,"marketCap":1156609382},{"date":"2026-03-27","current":-7.36551,"twenty":-98.861547,"median":-80.41388,"eighty":-7.003988,"marketCap":1545571323},{"date":"2026-04-02","current":-7.207452,"twenty":-96.587906,"median":-7.443103,"eighty":-7.019507,"marketCap":1512404556},{"date":"2026-04-10","current":-7.670132,"twenty":-94.238224,"median":-7.361199,"eighty":-7.021806,"marketCap":1609492728},{"date":"2026-04-17","current":-7.759219,"twenty":-89.113027,"median":-7.443103,"eighty":-7.088477,"marketCap":1628186724},{"date":"2026-04-24","current":-7.305161,"twenty":-78.931071,"median":-7.519258,"eighty":-7.200555,"marketCap":1532907649},{"date":"2026-05-01","current":-7.374132,"twenty":-59.951712,"median":-7.420112,"eighty":-7.071235,"marketCap":1547380419},{"date":"2026-05-08","current":-7.181588,"twenty":-7.748873,"median":-7.369821,"eighty":-7.098823,"marketCap":1506977267},{"date":"2026-05-15","current":-6.125513,"twenty":-7.702318,"median":-7.328151,"eighty":-6.979849,"marketCap":1440040702},{"date":"2026-05-22","current":-6.376895,"twenty":-7.679328,"median":-7.296539,"eighty":-6.874668,"marketCap":1499137850},{"date":"2026-05-29","current":-6.50384,"twenty":-7.670132,"median":-7.208889,"eighty":-6.624282,"marketCap":1528981338},{"date":"2026-06-05","current":-5.841412,"twenty":-7.647141,"median":-7.181588,"eighty":-6.506459,"marketCap":1373251758},{"date":"2026-06-12","current":-5.592674,"twenty":-7.644267,"median":-7.103996,"eighty":-6.310202,"marketCap":1314776223},{"date":"2026-06-18","current":-5.608384,"twenty":-7.605184,"median":-7.036462,"eighty":-6.158347,"marketCap":1318469415},{"date":"2026-06-26","current":-5.909488,"twenty":-7.595413,"median":-6.974676,"eighty":-5.98699,"marketCap":1389255588},{"date":"2026-07-02","current":-7.092956,"twenty":-7.5092,"median":-6.96318,"eighty":-6.007936,"marketCap":1667476025},{"date":"2026-07-10","current":-8.059107,"twenty":-7.645417,"median":-7.006288,"eighty":-6.078901,"marketCap":1894607311},{"date":"2026-07-17","current":-7.917719,"twenty":-7.67473,"median":-7.092956,"eighty":-6.150138,"marketCap":1861368586},{"date":"2026-07-24","current":-7.637561,"twenty":-7.776537,"median":-7.12986,"eighty":-6.183485,"marketCap":1795506668},{"date":"2026-07-31","current":-7.648035,"twenty":-7.738833,"median":-7.190209,"eighty":-6.195797,"marketCap":1797968796},{"date":"2026-08-07","current":-7.82346,"twenty":-7.815082,"median":-7.208161,"eighty":-6.219919,"marketCap":1839209436},{"date":"2026-08-14","current":-7.218207,"twenty":-7.815082,"median":-7.209243,"eighty":-6.276357,"marketCap":1897132498},{"date":"2026-08-21","current":-7.119553,"twenty":-7.785196,"median":-7.218207,"eighty":-6.321676,"marketCap":1871203580},{"date":"2026-08-28","current":-7.187671,"twenty":-7.738833,"median":-7.209243,"eighty":-6.354091,"marketCap":1889106881},{"date":"2026-09-04","current":-6.576954,"twenty":-7.707949,"median":-7.198831,"eighty":-6.380999,"marketCap":1728594532},{"date":"2026-09-09","current":-6.851777,"twenty":-7.707644,"median":-7.192369,"eighty":-6.385103,"marketCap":1800825089}],"updateTime":1789038388155},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DMRA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664871738","title":"Damora Therapeutics Grants New Hires Options for 135,400 Shares at $28.18 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2664871738","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664871738?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:03","pubTimestamp":1788437010,"startTime":"0","endTime":"0","summary":"Damora Therapeutics grants new hires options for 135,400 shares at $28.18 eachDamora Therapeutics granted options covering 135,400 ordinary shares to three newly hired, non-executive employees on Sept","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL1vqH7B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","IE00BKPKM429.USD","LU2095319765.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","BK4112","IE00BN0W2W23.USD","LU0314104364.USD","BCDF","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","DMRA","BK4588","SG9999014005.SGD","SG9999014021.USD","BK4139","LU2210149790.SGD","NDAQ","IE00B64PRP62.GBP","BK4585","LU2210150020.SGD","SG9999014039.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664787192","title":"Damora Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664787192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664787192?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:00","pubTimestamp":1788436802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA36P6WC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664877191","title":"Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664877191","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664877191?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:00","pubTimestamp":1788436800,"startTime":"0","endTime":"0","summary":"BOSTON, Sept.  03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/03/3355814/0/en/damora-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","LCLG","LENZ","BK4007","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660329924","title":"Top News Today: Stocks Fall, Oil Rises as US-Iran Tensions Mount","url":"https://stock-news.laohu8.com/highlight/detail?id=2660329924","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660329924?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:35","pubTimestamp":1786998900,"startTime":"0","endTime":"0","summary":"MARKET WRAPSSTOCKS: Stocks fell as tensions mounted between the U.S. and Iran.TREASURYS: Treasury yields rose and the yield on the 30-year bond closed at the highest level since 2007 due to inflation ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PURR","BK4588","LU2322448957.HKD","IE0031619046.USD","MPU","TOL","BK4124","LU1992135472.HKD","IRIX","RBOT","BK4187","LU2272731600.USD","BK4139","BK4157","BK4585","JKHY","MRCY","BK4524","DMRA","ITB","LZB","IE00BN0W2T93.GBP","BK4082","BK4113","BK4075","BK4227","IE00B7SZL793.SGD","WINSF","LU1815336091.USD","KEYS","IE00BMPRXN33.USD","IE00BN0W2W23.USD","BK4515","BK4108","LU2272731782.SGD","BK4600","LU1983260115.SGD","BK4095","LU2473716301.USD","BK4088","IE00B66KJ199.SGD","LU0054578231.USD","SYPR","LU0757428866.USD","LU1992135399.USD","LU1894683348.USD","ANAB","HCMC","BK4106","AVXL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660155170","title":"Damora Therapeutics (DMRA) Starts CLARITY 101 Trial With Valuation Still In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2660155170","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660155170?lang=en_us&edition=fundamental","pubTime":"2026-08-17 01:23","pubTimestamp":1786900987,"startTime":"0","endTime":"0","summary":"Damora Therapeutics (DMRA) has started the global Phase 1/1b CLARITY-101 trial of DMR-001, an investigational antibody that targets mutant calreticulin in essential thrombocythemia and myelofibrosis, representing a rare targeted approach in these blood disorders.\nSee our latest analysis for Damora Therapeutics.\nAt a recent share price of US$31.04, Damora Therapeutics has seen strong momentum, with a 90 day share price return of 24.66% and a very large 1 year total shareholder return that...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmra/damora-therapeutics/news/damora-therapeutics-dmra-starts-clarity-101-trial-with-valua","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmra/damora-therapeutics/news/damora-therapeutics-dmra-starts-clarity-101-trial-with-valua","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","DMRA","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659902160","title":"Damora Therapeutics Director Andrew Cheng Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2659902160","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659902160?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:57","pubTimestamp":1786654677,"startTime":"0","endTime":"0","summary":"Damora Therapeutics director Andrew Cheng files initial beneficial ownership statementDamora Therapeutics director Andrew Cheng filed an initial Form 3 on Aug. 13, 2026.Disclaimer:This news brief was ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL1VgJLw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658919079","title":"Jefferies Reaffirms Their Buy Rating on Damora Therapeutics (DMRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658919079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658919079?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:57","pubTimestamp":1786460223,"startTime":"0","endTime":"0","summary":"In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Damora Therapeutics, with a price target of $50.00. Tewari cover...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-reaffirms-their-buy-rating-on-damora-therapeutics-dmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-reaffirms-their-buy-rating-on-damora-therapeutics-dmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DMRA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658919005","title":"Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Damora Therapeutics (DMRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658919005","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658919005?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:50","pubTimestamp":1786459809,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Olema Pharmaceuticals (OLMA), Damora Therapeutics (D...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-olema-pharmaceuticals-olma-damora-therapeutics-dmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-olema-pharmaceuticals-olma-damora-therapeutics-dmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OLMA","DMRA","BK4505","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951442","title":"Damora Therapeutics Posts Corporate Deck on mutCALR-Targeted Therapies for Myeloproliferative Neoplasms","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951442","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951442?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:39","pubTimestamp":1786394374,"startTime":"0","endTime":"0","summary":"Damora Therapeutics posts corporate deck on mutCALR-targeted therapies for myeloproliferative neoplasmsDamora outlined a mutCALR-focused pipeline for myeloproliferative neoplasms, targeting essential thrombocythemia and myelofibrosis.Lead antibody DMR-001 entered Phase 1/1b CLARITY-101, with two proof-of-concept readouts expected beginning mid-2027.Damora reported about $541 million in cash to fund DMR-001 through proof-of-concept and into registrational development.DMR-002, an Fc-enhanced anti-mutCALR antibody, is slated for a first regulatory submission in 2H 2026; DMR-003 targeted in 2027.The deck pegged the US mutCALR-driven MPN opportunity at more than $5 billion, citing roughly 42,000 prevalent patients across ET and MF.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL3BnlKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959553","title":"Press Release: Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959553","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959553?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:06","pubTimestamp":1786392360,"startTime":"0","endTime":"0","summary":"tolerability and efficacy of DMR-001 in patients with mutCALR-driven ET. and MF, based on receipt of health authority approval. The Phase 1 dose. escalation portion of the trial is designed to rapidly identify a. recommended dose for expansion cohorts, with a starting dose of 100 mg.  expected to be in the range of anticipated. therapeutic exposure and an adaptive Bayesian design enabling cohort. enrichment. The planned Phase 1b expansion portion of the trial will. further evaluate the safety and efficacy of DMR-001 in additional. populations and settings, including in early-line disease and in. combination with other therapies. Read the press release here.-- Presented DMR-001 preclinical data at the EHA 2026 Congress (Abstract. preclinical studies versus a reference anti-mutCALR antibody, DMR-001. showed up to 30-fold higher binding affinity for mutCALR, 26-fold greater. inhibition of cellular proliferation in Type 2 mutCALR, an","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMLP","TPZ","BK4106","BK4561","EIPX","BK4007","AMLP","MF","AMZA","BK4526","USAI","ENFR","BK4144","BK4590","DMRA","ET","BK4539","TNGY","BK4226","MLPA","BK4563","LENZ","BK4581","EIPI","BK4588","XELA","MDST","BK4113","BK4139","BK4585","BK4134","UMI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658956254","title":"Damora Q2 Net Loss Widens to $31.17 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658956254","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658956254?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:04","pubTimestamp":1786392249,"startTime":"0","endTime":"0","summary":"Damora Q2 net loss widens to $31.17 millionDamora posted a GAAP net loss of USD 31.17 million for the quarter ended June 30, 2026, widening from USD 3.44 million a year earlier.Operating loss widened ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL2Nf1Qw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657615553","title":"Wedbush Keeps Their Buy Rating on Damora Therapeutics (DMRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657615553","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657615553?lang=en_us&edition=fundamental","pubTime":"2026-08-07 16:08","pubTimestamp":1786090097,"startTime":"0","endTime":"0","summary":"In a report released yesterday, David Nierengarten from Wedbush maintained a Buy rating on Damora Therapeutics, with a price target of $40.00. The ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-damora-therapeutics-dmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-damora-therapeutics-dmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657523027","title":"Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2657523027","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657523027?lang=en_us&edition=fundamental","pubTime":"2026-08-05 22:42","pubTimestamp":1785940975,"startTime":"0","endTime":"0","summary":"Damora Therapeutics  said Wednesday it initiated a global Phase 1/1b clinical trial of DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis.The open-label, multicenter CLARITY-101 study will evaluate the safety, tolerability and preliminary efficacy of the investigational monoclonal antibody therapy.The dose-escalation portion will begin with a 100-milligram monthly subcutaneous dose and is designed to identify a recommended dose for further development.A planned expansion phase will assess DMR-001 in additional patient groups, earlier treatment settings and combinations with other therapies.Damora expects to report initial trial data beginning in mid-2027, the biotechnology company said.Price: 30.84, Change: +0.82, Percent Change: +2.71","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDST","BK4226","BK4144","BK4561","BK4585","USAI","TNGY","BK4588","EIPX","XELA","BK4581","ENFR","LENZ","EIPI","BK4106","EMLP","TPZ","AMZA","UMI","DMRA","AMLP","BK4590","BK4007","BK4539","MLPA","ET","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657541907","title":"Damora Therapeutics Initiates Phase 1/1B Clarity-101 Clinical Trial of Dmr-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2657541907","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657541907?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:00","pubTimestamp":1785931203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA5SFKJR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657541410","title":"Damora Therapeutics - Expects Initial Clarity-101 Trial Data Beginning Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2657541410","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657541410?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:00","pubTimestamp":1785931203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA5SFKJR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656309754","title":"Damora Therapeutics Grants 451,000 Inducement Stock Options at $28.99 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2656309754","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656309754?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:01","pubTimestamp":1785787275,"startTime":"0","endTime":"0","summary":"Damora Therapeutics grants 451,000 inducement stock options at $28.99 per shareDamora Therapeutics granted inducement stock options covering 451,000 ordinary shares to six newly hired, non-executive e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL5Cvm7d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","LU2210149790.SGD","LU2095319765.USD","BK4139","IE00B3QW5Z07.USD","LU0314104364.USD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","SG9999014013.SGD","BK4588","IE00BN0W2T93.GBP","BK4112","SG9999014021.USD","DMRA","BCDF","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656309788","title":"Damora Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656309788","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656309788?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:01","pubTimestamp":1785787260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUA210CXG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656307898","title":"Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656307898","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656307898?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:01","pubTimestamp":1785787260,"startTime":"0","endTime":"0","summary":"BOSTON, Aug.  03, 2026  (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337851/0/en/Damora-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4007","DMRA","LCLG","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654701327","title":"U.S. Research ROUNDUP-Blackstone, Hartford Insurance, Zevra Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2654701327","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654701327?lang=en_us&edition=fundamental","pubTime":"2026-07-27 16:55","pubTimestamp":1785142545,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Blackstone, Hartford Insurance, Zevra TherapeuticsJuly 27 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, incl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4N43T0K1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHTR","FRBA","BX","FTNT","FMBH","AXPG","BAX","AMAL","DMRA","FCNCA","CUBI","AAL","VGSR","FVCB","HIG","CPF","FHB","FUTY","AALG","FISI","GM","HON","AXP","SRCE","FLG","FTAI","AAPW","CLF","CYH","AAPL","AAPB","HWM","CIBR","REET","REAI","BAH","AGIO","CDRE","CELC","BAM","BWXT","TRUU","CATY","DLR","BY","EBC","F","BANR","ARLO","CEG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654949000","title":"Damora Therapeutics Inc (pre-reincorporation) : Jefferies Initiates Coverage with Buy Rating; Price Target $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2654949000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654949000?lang=en_us&edition=fundamental","pubTime":"2026-07-27 14:02","pubTimestamp":1785132174,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nFWN43T0JL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":73,"code":"91000000","status":"200"}]}}